State Of The Art Functional Imaging In Sickle Cell Disease

St. Jude Children's Research Hospital38 enrolled

Overview

Sickle cell anemia (SCA) is a serious blood disease with blood vessel changes leading to brain injury and stroke. Studies show about 11% of patients with SCA will develop obvious stroke before age 20 years, with children less than 10 years of age especially vulnerable. The main objective of the SCDMR4\[State Of The Art Functional Imaging In Sickle Cell Disease\] trial is to compare the gray matter cerebral blood flow, measured by MRI,\[magnetic resonance imaging\] ASL \[Arterial Spin Labeling\] perfusion before treatment begins and after the appropriate hydroxyurea dosage is reached (\~ one year). Other important objectives of the SCDMR4 trial include describing the effect of hydroxyurea therapy and transfusion therapy on the functional MRI response, diffusion tensor imaging of white matter, brain function, and transcranial Doppler blood velocities.

The Primary Objective of the study is to compare the research participant's GM \[Gray Matter\] CBF \[Cerebral Blood Flow\] by ASL \[Arterial Spin Labeling\] techniques before and after reaching a stable hydroxyurea MTD \[Maximum Tolerated Dose\] (12±3 months after starting hydroxyurea). This is an observational study. Participants receive hydroxyurea as part of their standard of care treatment. This study will observe the above measures prior to beginning hydroxyurea and after participants reach the maximum tolerated dose in order to describe the effect of therapy on the participants' functional response.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sickle Cell Anemia

Eligibility

Sex: ALLMin age: 5 YearsMax age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria for Pre-Hydroxyurea or Pre-Transfusion Therapy Study Participants: 1. The diagnosis of HbSS or HbS/ß0-thalassemia 2. Age: 8.0 -- \<19 years old Inclusion Criteria for Study Participants for Observation: 1. The diagnosis of HbSS or HbS/ß0-thalassemia 2. Age: 8.0 -- \<19 years old Inclusion Criteria for Study Participants for Family Related Controls: 1. No diagnosis of HbSS or HbS/ß0-thalassemia 2. Age: 8.0 -- \<19 years old Exclusion Criteria for Pre-Hydroxyurea or Pre-Transfusion Therapy Study Participants: 1. Unable to tolerate the anatomical or fMRI \[functional magnetic resonance imaging\] without sedation or anesthesia 2. Currently receiving hydroxyurea therapy or transfusion therapy 3. Previous stem cell transplant or other myelosuppressive therapy 4. History of clinical stroke 5. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent/assent. Exclusion Criteria for Study Participants for Observation: 1. Unable to tolerate anatomical or fMRI components without sedation or anesthesia 2. Currently receiving hydroxyurea or transfusion therapy 3. Previous stem cell transplant or other myelosuppressive therapy 4. History of clinical stroke 5. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. Exclusion Criteria for Study Participants for Family Related Controls: 1. Unable to tolerate anatomical or fMRI components without sedation or anesthesia 2. Currently receiving hydroxyurea or transfusion therapy 3. Previous stem cell transplant or other myelosuppressive therapy 4. History of clinical stroke 5. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Outcomes

Primary Outcomes

Change in cerebral blood flow

Change in gray matter cerebral blood flow measured by arterial spin labeling techniques from before (baseline) to after reaching a stable hydroxyurea maximum tolerated dose.

Time frame: from baseline to 12 +/- 3 months

Secondary Outcomes

Change in cerebral blood flow by territory

Change in gray matter cerebral blood flow in individual anterior cerebral artery, middle cerebral artery, and posterior cerebral artery territories, and hemispheric gray matter measured by arterial spin labeling techniques from before (baseline) to after reaching a stable hydroxyurea maximum tolerated dose.

Time frame: From baseline to 12 +/- 3 months